Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries

By afschroeder • November 23, 2025

Bolla E, Semb AG, Petri M, Sfikakis PP, Artim-Esen B, Hernandez-Molina G, Hachulla E, Direskeneli H, Karpouzas GA, Zucchi D, Goyal M, Costedoat-Chalumeau N, Tincani A, Yazici A, Lerang K, Troldborg A, Ajeganova S, Popkova TV, Svenungsson E, Pantazis N, Tektonidou MG; SURF-SLE and APS collaborators. Cardiovascular risk factor control in antiphospholipid syndrome, and differences between primary and systemic lupus erythematosus-related antiphospholipid syndrome (SURF-SLE and APS project): a cross-sectional study of 1003 individuals from 11 countries. Lancet Rheumatol. 2025 Nov 19:S2665-9913(25)00257-7. doi: 10.1016/S2665-9913(25)00257-7. Epub ahead of print. PMID: 41274305.

Tags: Harbor UCLA, Publications, Rheumatology

Whole Genome Sequence Analysis of Weight Loss in 16 972 Participants With COPD Reveals Novel Risk Loci in DRAIC and RFX3

Chiles JW 3rd, Rocco A, Srinivasasainagendra V, Rossiter HB, Casaburi R, Thalacker-Mercer A, Wells JM, Wan ES, Silverman EK, Cho MH, Hersh CP, Psaty BM,[...]

Association of Intravenous Versus Oral Iron Therapy With Clinical Outcomes in Patients With Advanced CKD

Adeboye AM, Shrestha P, Sumida K, Thomas F, Rhee CM, Kalantar-Zadeh K, Kovesdy CP. Association of Intravenous Versus Oral Iron Therapy With Clinical Outcomes in[...]

Evolocumab for Primary Prevention of Cardiovascular Disease

Budoff MJ, Iskander B. Evolocumab for Primary Prevention of Cardiovascular Disease. N Engl J Med. 2026 Apr 23;394(16):1658. doi: 10.1056/NEJMc2602103. PMID: 42019029.